4.8 Article

The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C

Journal

SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 622, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abg2919

Keywords

-

Funding

  1. Department of Veterans Affairs
  2. National Institute on Aging [RF1-AG064897-02, F30AG060638, T32AG000266]
  3. UCI-ADRC [NIA P30 AG066519]
  4. National Institute of General Medical Sciences [R01-GM058867, K00CA212454]
  5. NOMIS Foundation
  6. Glenn Foundation for Aging Research
  7. NYSCF Robertson Stem Cell Investigator Award
  8. Stanford Wu Tsai Neurosciences Big Idea Project on Human Brain Organogenesis
  9. Zuckerberg Initiative Ben Barres Investigator Award
  10. Wu Tsai Neurosciences Institute

Ask authors/readers for more resources

The dysfunction of lysosomes is a common feature in both rare lysosomal storage diseases and common age-related neurodegenerative diseases. A study found that CD22 is expressed in oligodendrocytes in the human brain and binds to sialic acid-dependent ligands on microglia. Interaction between sCD22 and IGF2R disrupts lysosomal protein trafficking, and interference with this interaction improved lysosome dysfunction in human NPC1 mutant cells.
Lysosome dysfunction is a shared feature of rare lysosomal storage diseases and common age-related neuro-degenerative diseases. Microglia, the brain-resident macrophages, are particularly vulnerable to lysosome dysfunction because of the phagocytic stress of clearing dying neurons, myelin, and debris. CD22 is a negative regulator of microglial homeostasis in the aging mouse brain, and soluble CD22 (sCD22) is increased in the cerebrospinal fluid of patients with Niemann-Pick type C disease (NPC). However, the role of CD22 in the human brain remains unknown. In contrast to previous findings in mice, here, we show that CD22 is expressed by oligodendrocytes in the human brain and binds to sialic acid-dependent ligands on microglia. Using unbiased genetic and proteomic screens, we identify insulin-like growth factor 2 receptor (IGF2R) as the binding partner of sCD22 on human myeloid cells. Targeted truncation of IGF2R revealed that sCD22 docks near critical mannose 6-phosphate-binding domains, where it disrupts lysosomal protein trafficking. Interfering with the sCD22-IGF2R interaction using CD22 blocking antibodies ameliorated lysosome dysfunction in human NPC1 mutant induced pluripotent stem cell-derived microglia-like cells without harming oligodendrocytes in vitro. These findings reinforce the differences between mouse and human microglia and provide a candidate microglia-directed immunotherapeutic to treat NPC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available